I.CERAM SA (FR:ALICR) has released an update.
I.Ceram SA reported a 46% decline in revenue for the first half of 2024, attributed to the loss of certification for key products, while operating losses grew despite cost-cutting measures. The company is focusing on advancing antibiotic-loaded ceramic implants and is in the process of judicial recovery, with a restructuring plan due in November. Listed on Euronext Growth, I.Ceram is leveraging its innovative bioceramic technologies to drive future growth.
For further insights into FR:ALICR stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
